Advertisement

ImmunoPrecise Antibodies Ltd. IPA

Set alert

Price alert · IPA

All alert types
1.62 0.00 0.00%

As of Oct 20, 2:54 PM ET

1.56 Day range 1.65
0.325 52-week range 2.60
Open
1.65
Prev close
1.62
Mkt cap
12.39M
Vol
55.66K
Avg vol
558.86K
EPS
-0.75
P/E
0.00
Div yield
0.00%
More statistics
Low
1.56
High
1.65
Forward P/E
-2.49
Beta
0.27
Short ratio
0.70
Inst. own
6.58%
Dividend
0.00
Ex-div date
Earnings
Sep 16, 2024
50-d avg
0.452
200-d avg
0.882795
1y target
5.00

2Y chart

Chart tools
Interval

Chart is warming up

The two-year price history for IPA has not been loaded yet. Try again in a moment.

Key statistics

Market cap
12.39M
Enterprise value
23.90M
Trailing P/E
0.00
Forward P/E
-2.49
PEG ratio
0.00
Price / sales
0.51
Price / book
0.32
EPS (TTM)
-0.75
Beta
0.27
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
-115.22%
Revenue (TTM)
24.09M
Revenue growth
-7.50%
Free cash flow
-808.50K
Total cash
3.91M
Total debt
16.10M
Return on equity
-64.04%
Shares outstanding
31.06M
Short % of float
2.41%
50-day average
0.452
200-day average
0.882795

Analyst view

Consensus: buy

Buy
Price target (mean) 5.00 +208.6% upside
Target (low)
3.00
Target (mean)
5.00
Target (high)
7.00
Ratings (0m) 2 2 buy · 0 hold · 0 sell
  • Strong buy2
  • Buy0
  • Hold0
  • Sell0
  • Strong sell0

Next earnings

Sep 16, 2024

Expected Sep 16, 2024. Consensus EPS estimate 0.00.

Earnings history

Financials — quick view

All financials
IPA Revenue — quarterly 6.98M
2022-Q1 20212022-Q2 20212022-Q3 20212022-Q4 20222023-Q1 20222023-Q2 20222023-Q3 20222023-Q4 20232024-Q1 20232024-Q2 20232024-Q3 20232024-Q4 20242025-Q1 20242025-Q2 20242025-Q3 20242025-Q4 2025
IPA Net income — quarterly -2.16M
2022-Q1 20212022-Q2 20212022-Q3 20212022-Q4 20222023-Q1 20222023-Q2 20222023-Q3 20222023-Q4 20232024-Q1 20232024-Q2 20232024-Q3 20232024-Q4 20242025-Q1 20242025-Q2 20242025-Q3 20242025-Q4 2025
IPA EPS — quarterly -0.05
2022-Q1 20212022-Q2 20212022-Q3 20212022-Q4 20222023-Q1 20222023-Q2 20222023-Q3 20222023-Q4 20232024-Q1 20232024-Q2 20232024-Q3 20232024-Q4 20242025-Q1 20242025-Q2 20242025-Q3 20242025-Q4 2025

Earnings

IPA recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Dec 10, 2024Oct 1, 2024-0.05-0.07-0.02-40.00%
Sep 16, 2024Jul 1, 2024-0.09———
Sep 16, 2024Jul 1, 2024-0.09-0.11-0.02-22.22%
Jul 29, 2024Apr 1, 2024-0.10———
Jul 29, 2024Apr 1, 2024-0.10-0.52-0.42-420.00%
Mar 14, 2024Jan 1, 2024-0.08-0.080.000.00%

Upgrades / downgrades

IPA analyst upgrades and downgrades
DateFirmActionFromTo
Dec 11, 2024HC Wainwright & Co.mainBuyBuy
Sep 17, 2024HC Wainwright & Co.reitBuyBuy
Aug 14, 2024BenchmarkmainSpeculative BuySpeculative Buy
Jul 30, 2024HC Wainwright & Co.reitBuyBuy
Mar 15, 2024BenchmarkreitSpeculative BuySpeculative Buy
Mar 15, 2024HC Wainwright & Co.reitBuyBuy

About ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd., a biotechnology company, leverages multi-omics modeling and artificial intelligence through a series proprietary and patented technologies. The company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; peptide production for subsequent antibody discovery campaign; B cell select platform, which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. In addition, it provides phage display, a custom immune library; CAR development, an adaptable antibody, which allows the inclusion of functional data early in the screening funnel; antibody sequencing; and assay development. Further, it offers a profiling toolset for antibody lead candidates; and in vitro analytical tools for the study of quality attributes. Additionally, it provides LucinaTech, an antibody humanization to identify framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; antibody chimerization for cloning and production of antibody domain; Eurofins preclinical services; hybrid service model designed to reduce time and risk with custom applications; breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts; and protein manufacturing services. The company is headquartered in Victoria, Canada.

Sector
Healthcare
Industry
Biotechnology
Country
Canada

News

No recent headlines

Headlines appear here as they are published.

Your note

Sign in to keep a note on IPA — it syncs with the Stock Master app.

Institution ownership

IPA institution ownership
Holder% heldSharesValueReported
Ingalls & Snyder5.41%1,558,892622.00KSep 29, 2024
Renaissance Technologies, LLC0.21%60,30024.06KSep 29, 2024
Bank of Montreal /CAN/0.20%57,80723.06KSep 29, 2024
Northern Trust Corporation0.18%50,73020.24KSep 29, 2024
Cibc World Markets, Inc.0.14%41,20016.44KSep 29, 2024
Gradient Capital Advisors, LLC0.09%26,80810.70KSep 29, 2024

Fund ownership

IPA fund ownership
Holder% heldSharesValueReported
Fidelity NASDAQ Composite Index Fund0.06%17,4846.98KOct 30, 2024
Advertisement